XGenomes

XGenomes, formerly known as XGenomes Corp., is located in Cambridge, MA, USA, and has a secondary location in Cambridge, UK. The company operates within the healthcare industry, specifically focusing on diagnostics. XGenomes is a small team of six professionals who participated in the Y-Combinator W19 batch. The company’s innovative approach to DNA sequencing utilizes novel biochemistry, hardware, and algorithms to offer features such as zero library preparation, direct sequencing on single molecules, and integrated DNA extraction with sequencing. XGenomes aims to achieve unprecedented accuracy by concurrently sequencing both strands of the DNA double-helix. Their technology targets various genetic components including structural and single nucleotide variants, long-range haplotype phase, and the repetitive ‘dark matter’ of the genome. With a targeted cost of goods for sequencing under $10, XGenomes plans to initially provide access to its services to high-value customers through a service model, followed by a product sales model involving instruments and consumables. The company’s mission is to make their DNA sequencing platform accessible throughout an individual’s lifetime for continuous health monitoring and disease detection, supporting their presence in regions such as the United States, America/Canada, and offering remote and partly remote services.